Na Gao

600# TianHe Road
Guangzhou, 510630, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

MRI-based clinical-radiologic model to predict the efficacy and prognosis of interventional with systemic therapy in advanced hepatocellular carcinoma: a multicenter study.

MRI-based clinical-radiologic model to predict the efficacy and prognosis of interventional with systemic therapy in advanced hepatocellular carcinoma: a multicenter study.

Journal: Journal of translational medicine

Published: December 05, 2025

Correction: Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss.

Correction: Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss.

Journal: Virology journal

Published: May 31, 2025

Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss.

Nucleos(t)ide analogs continuation is not associated with a lower risk of HBsAg seroreversion following PEG-IFN-induced HBsAg loss.

Journal: Virology journal

Published: January 11, 2025

SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α-Based Therapy on Chronic Hepatitis B.

SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α-Based Therapy on Chronic Hepatitis B.

Journal: The Journal of infectious diseases

Published: October 16, 2024

Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level.

Interferon-α could induce liver steatosis to promote HBsAg loss by increasing triglyceride level.

Journal: Heliyon

Published: February 06, 2024

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion.

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion.

Journal: JHEP reports : innovation in hepatology

Published: November 23, 2023

Editorial: HBsAg seroclearance after pegylated interferon treatment-The beginning of the end. Authors' reply.

Editorial: HBsAg seroclearance after pegylated interferon treatment-The beginning of the end. Authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: October 27, 2023

Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B.

Higher TP53BP2 expression is associated with HBsAg loss in peginterferon-α-treated patients with chronic hepatitis B.

Journal: Journal of hepatology

Published: December 27, 2022

Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy.

Integrated HBV DNA and cccDNA maintain transcriptional activity in intrahepatic HBsAg-positive patients with functional cure following PEG-IFN-based therapy.

Journal: Alimentary pharmacology & therapeutics

Published: December 15, 2022

Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy.

Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon-based therapy.

Journal: Journal of viral hepatitis

Published: April 26, 2022

Reduction in Intrahepatic cccDNA and Integration of HBV in Chronic Hepatitis B Patients with a Functional Cure.

Reduction in Intrahepatic cccDNA and Integration of HBV in Chronic Hepatitis B Patients with a Functional Cure.

Journal: Journal of clinical and translational hepatology

Published: April 12, 2022

Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.

Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients.

Journal: Journal of viral hepatitis

Published: February 16, 2022

Showing 1-12 of 13

Last Updated: 09/26/2026